Opening this new window of therapeutic opportunities has great potential to overcome early and advanced HER2+ breast cancer resistance to small molecular inhibitors of HER2, as well as to improve the efficacy of mAbs in first-line treatment. This evidence concerns the gene ERBB2 and breast carcinoma.